Apricus Biosciences (NASDAQ:APRI) was upgraded by Zacks Investment Research from a “strong sell” rating to a “hold” rating in a research note issued on Wednesday.

According to Zacks, “Apricus Bio operates in the pharmaceutical industry and focuses on research and development in the area of drug delivery. Its proprietary drug delivery technology is called NexACT ®. Backed by revenue generating CRO business, Bio-Quant, Inc. and its NexMed USA subsidiary, Apricus Bio has leveraged the flexibility of its proven NexACT® drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes. The Company is seeking to monetize its existing product pipeline, including compounds from pre-clinical through Phase 3, currently focused on dermatology, sexual dysfunction and cancer. Apricus Bio was formerly known as NexMed, Inc and is headquartered in San Diago, California. “

Separately, HC Wainwright reiterated a “buy” rating and set a $4.50 price objective on shares of Apricus Biosciences in a research note on Friday, November 3rd.

Apricus Biosciences (NASDAQ:APRI) traded up $0.18 during midday trading on Wednesday, hitting $2.02. 918,900 shares of the company traded hands, compared to its average volume of 569,750. The company has a market cap of $28.00, a price-to-earnings ratio of 3.48 and a beta of 0.43. Apricus Biosciences has a 1 year low of $0.86 and a 1 year high of $4.07.

Apricus Biosciences (NASDAQ:APRI) last posted its quarterly earnings data on Thursday, November 2nd. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.15). During the same period in the previous year, the company posted ($0.19) EPS. analysts expect that Apricus Biosciences will post -0.6 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Apricus Biosciences (APRI) Upgraded to Hold at Zacks Investment Research” was published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/apricus-biosciences-apri-upgraded-to-hold-at-zacks-investment-research/1793233.html.

Apricus Biosciences Company Profile

Apricus Biosciences, Inc is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT.

Receive News & Ratings for Apricus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences and related companies with Analyst Ratings Network's FREE daily email newsletter.